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Abstract
Background: During mammography, the thyroid is exposed to scattered radiation from breast tissue and the
device. This may increase the risk of radiation induced thyroid cancer.
Methods: We investigated the scatter radiation exposition of the thyroid and the effect of a tailored thyroid
protection in phantom and patient as well as by using Monte Carlo simulation (MCS). The protective effect of a
modified thyroid protection, the relevance of the protective effect and acceptance by patients have been
investigated.
Results: Phantom and patient measurements provided higher values for the surface dose at thyroid position than
expected from MCS (phantom 0.32 mGy; patients 0.38 mGy; MCS 0.16 mGy). Phantom measurements indicated
scatter contributions from both breast tissue and collimator/tube system. The value found in our patient study is
within the range of the literature (0.22–0.39 mGy). The thyroid protection significantly reduced the surface dose but
the dose (0.016 mGy) was higher than that expected from the lead equivalent value. However, the impact of the
collar to the effective dose was small (< 4%). The collar was not visible on mammograms.
Conclusions: Scatter from the collimator/tube system contributed with 50% to the thyroid dose. Due to the relative
small fraction of dose deposited in the thyroid when compared to the mean glandular dose to the breast, a collar is
not mandatory in general. Not being associated with the risk of obscuring parts of mammograms, such a collar may be
used for young women considering their higher radio sensitivity.
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Key points
 Thyroid dose during mammography was higher
than that expected by MCS and the literature
 Radiation from the collimator/tube system
contributed approximately 50% to the thyroid dose
 Tailored thyroid protection significantly reduced
radiation exposure to the thyroid and was not visible
on mammograms
 Thyroid protection is not mandatory but may be
taken into consideration for young women
Background
Mammography is the most important breast examination
technique for screening and diagnostic purposes. The ab-
dominal dose during mammography is extremely low [1],
making the use of a lead apron for abdominal protection
questionable. The thyroid is more exposed to scattered
radiation coming from breast tissue (backscatter) and from
the device (scatter from the collimator system and leakage
radiation).
Radiation exposure of the thyroid, especially at a young
age, is a recognised risk factor for the development of
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thyroid cancer [2, 3]. It was postulated that the increased
incidence of thyroid cancer in females might be partially at-
tributed to exposure from medical radiation, including
computed tomography and mammography [1, 3, 4]. Of
note, due to the low tube voltage used for mammography,
absorption in the tissue and backscatter are high. The first
effect (caused by the prevalent photoelectric effect) protects
the thyroid by the absorption by the overlaying tissue. The
second effect (Thomson scattering, high probability of
backscatter) contributes significantly to the scatter. Back-
scatter is dependent on patient anatomy, especially breast
size, breast density and, related to this, breast compression.
The dose to the breast was investigated by Hendrik et
al. [5, 6] while the thyroid dose and surface dose at thyroid
position acquired during mammography were investigated
by Sechopoulos [1], Whelan et al. [7], Chetlen et al. [8]
and Kunosic et al. [9]. In the study by Whelan et al. [7],
the radiation dose to the skin overlying the thyroid for 91
women undergoing routine screening mammography was
measured while the study by Chetlen et al. [8] included
207 women. Baptista et al. [10] compared exposition of or-
gans caused by digital mammography and digital breast
tomosynthesis by measurements and Monte Carlo simula-
tion (MCS). For a bilateral digital mammography in cra-
niocaudal (CC) view, a thyroid dose of 0.273 mGy was
found by these authors.
Ramalho et al. [11] investigated the dose reduction to
the thyroid obtained by adopting a standard shielding col-
lar as those commonly used by interventional radiologists.
In that case, the problem is that the lower part of the thy-
roid collar can shadow parts of the breast. Therefore, we
tested in this study a modified thyroid protection in form
of a collar. Such a collar covers the neck, as all usual inter-
ventional collars do, but finishes at the jugulum height.
The measurements by Ramalho et al. using a General
Electric Senograph unit and an inflatable body phantom
showed a reduction of the entrance surface dose from 0.
16 mGy without protection to 0.018 mGy with protection.
Whelan et al. [7] found a large variability of skin dose
values (0.39 mGy ± 0.22 mGy, mean ± standard deviation),
resulting in a thyroid organ dose of approximately 0.
04 mGy; Chetlen et al. [8] reported doses from 0.05 mGy
to 0.82 mGy, with an average value of 0.25 mGy ± 0.
116 mGy (mean ± standard deviation). As a consequence,
we can assume that the patient anatomical variability has
an impact on the scatter dose contribution to the thyroid.
The aim of our study was to measure the dose contri-
bution from scatter to the thyroid and to evaluate the ef-
fect of a tailored thyroid protection, using a state-of-the
art digital mammography equipment. The following
points were investigated: (1) the protective effect of a
modified thyroid protection (is there a significant reduc-
tion of the surface dose at thyroid position, in particular
for a modern digital device with tungsten, instead of
molybdenum anode?); (2) relevance of such a protective
effect (reduction of thyroid dose compared to the breast
dose and effective dose estimated by MCS and expos-
ition parameters of the patient study); (3) acceptance by
patients and handling of protective device; and (4) influ-
ence of patient-individual parameters such as compres-
sion thickness to the thyroid exposure.
Methods
For the evaluation of the organ doses to the breast, thyroid
and ovaries, phantom and patient measurements have
been compared with MCS. All measurements have been
carried out on a Mammomat Inspiration unit (Siemens
Medical Solutions, Erlangen, Germany) using a tungsten
anode with rhodium filter. The device was equipped with
functions for optimisation of compression (OPCOMP®,
Siemens Medical Solutions, Erlangen, Germany) and ex-
posure (OPDOSE®, Siemens Medical Solutions, Erlangen,
Germany, Mammomat Inspiration Instruction Manual
XPW7-330.620.01.01.01). OPDOSE selects an optimal
combination of tube voltage (kV) and anode-filter com-
bination, based on the compression force and compres-
sion thickness found by OPCOMP and an automatic
exposure control image (short exposition before main
image acquisition). With increasing thickness, OPDOSE
regulates kV up to reduce time and dose.
Phantom study
The aims of phantom measurements were: (1) to deter-
mine the dependence of scatter on compression-
thickness, useful to compare surface dose with MCS and
patient study; and (2) to evaluate the spatial/angular
scatter contributions.
For the first point, an anthropomorphic Alderson
phantom [12] (Fig. 1) with a special breast extension for
compressed breast has been used (Fig. 1a): slabs of poly-
methylmethacrylate (PMMA) of 17 × 14 cm in size and
thickness of 4, 5, 6 or 7 cm, with the shape of a com-
pressed breast and with breast extension simulating the
uncompressed breast. Standard CC and mediolateral ob-
lique (MLO) views were acquired. The dose (air kerma)
at the position of the thyroid gland (scatter dose mean-
ing dose related to scattered radiation from breast tissue,
collimator, other components and leakage radiation from
the unit) has been investigated as a function of the com-
pression thickness by phantom measurements (Alderson
phantom with PMMA-slabs for mimicking compressed
breasts). The Alderson phantom is designed for radi-
ation therapy and therefore the densities are not exactly
tissue equivalent for low x-ray energies [12]. Dedicated
MCS of back scatter revealed a correction factor be-
tween 1.002 for muscle and 1.03 (28 kVp) or 1.04
(35 kVp) for lead for a scatter angle of 50° (maximum ef-
fect at this angle, s. section dosimeter calibration). When
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the phantom is only used to mimicking the back scatter
of a body representing the patient anatomy, this effect
can be neglected. The measurements were taken with an
RQM solid state detector (IBA Dosimetry GmbH,
Schwarzenbruck, Germany) directed to the beam ac-
cording to Fig. 1 (the RQM sensor does not see the full
dose but can indicate the relative increase).
For the second point, to evaluate scatter contributions
from breast tissue and collimator system, measurements
without Alderson phantom but with PMMA slabs and do-
simeters (IBA RQM and re-calibrated Automess SEQ-6R
[13], energy range from 18 keV to 3 MeV; section
dosimeter calibration) attached to a PMMA plate at thy-
roid positions have been carried out. To access informa-
tion about the angular distribution of scattered radiation,
measurements have been taken with and without a Pb-
shield which covers 180° of the sensitive chamber volume
and is directly attached to the dosimeter.
Patient study
The patient study was intended to investigate the influ-
ence of variability of patient anatomy on scattered dose
in front of and behind the thyroid protection. It was ap-
proved by the Ethical Committee at the Kantonsspital
Baden, Switzerland, and written informed consent was
obtained from all included patients. Patients scheduled
for screening or diagnostic mammography were eligible
in the absence of the following exclusion criteria: prior
operations of one or both breasts; visible asymmetries;
palpable lump; and breast implants. Three patients
refused participation. One was excluded after inspection
(visible breast asymmetry).
Measurements were taken with a modified thyroid
collar having a lead equivalent value of 0.25 mm
(Wiroma, Niederscherli, Switzerland). A total of 82 pa-
tients were categorised in three breast-size categories
based on the CC mammogram of the right breast: 27
large (L-group); 22 medium (M-group); and 33 small (S-
group). These criteria were based on a volumetric calcu-
lation using compression thickness, anteroposterior and
right-left dimensions previously measured in 40 mam-
mograms (unpublished data). Eleven patients in the L-
group and one patient in the M-group were studied with
the with 24 × 30 cm2 paddle; the remaining patients
were studied with the 18 × 24 cm2 paddle.
The thyroid collar and two SEQ-6R- dosimeters (see
phantom study) were fixed, one in front of and one
behind the thyroid collar in the neck midline (Fig. 2).
For each patient, the measurements were taken dur-
ing a two-view standard mammography of the left
breast. The application of thyroid collar and dosime-
ters as well as reading of the results after each meas-
urement were always performed by the same
examiner. The images were examined regarding qual-
ity and artefacts applying the PGMI-criteria (perfect,
good, moderate, inadequate) [14], as required for all
certified breast imaging centres in Switzerland. The
MGD values were calculated automatically for each
exposition by the Mammomat software and were reg-
istered for each examination.
Fig. 1 Measurements: on the left, with Alderson and breast phantom; on the right, geometry for measurements and MCS. The geometry is not
completely equal to the situation with real patients since the head of the Alderson phantom cannot be rotated to the side and for patient and
phantom measurement, the height of the image unit has to be adapted. The transparent shield, which is between the patient head and the
primary beam, was removed to allow a close position of the Alderson phantom, but was used for patient measurements and MCS.
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To evaluate the protective effect (air kerma behind the
collar compared to the air kerma value in front of the col-
lar), a paired t-test was used on the full sample as well as
on each of the three breast-size categories (L-group, M-
group and S-group). For comparisons among groups, a
one-way analysis of variance was used, followed by
Tukey’s range test. The statistical tests were applied to the
dose values measured in front of the collar as well as to
those measured behind the collar. Results with p values <
0.05 were interpreted as statistically significant. Since we
expected large breasts to yield more backscatter, we inves-
tigated the relationship between body mass index (BMI)
(associated with large breasts) and the air kerma in front
of the thyroid protection device.
Dosimeter calibration
Because of the high sensitivity at specific low-energy radi-
ation and radial isotropy (ability to measure backscatter),
we used Automess SEQ-6R dosimeters (energy range from
18 keV to 3 MeV; dose range 0.01–2.00 mGy). All dosime-
ters were re-calibrated by separated calibration measure-
ment for the radiation quality in use (30 kVp W-Rh target)
to the air kerma with a RQM detector (IBA Dosimetry
GmbH, Schwarzenbruck, Germany), with Dosimax plus
unit, range 500 nGy – 9999 mGy). Energy dependence and
linearity were checked by free air measurements with 20
kVp W-target. We compared the back scatter from muscle
tissue according to ICRP110 [15] and muscle tissue under a
layer of 0.25 mm Pb (collar lead equivalent) and under a
layer of 2.5 mm PMMA, irradiated with 28 and 35 keV W/
Rh x-rays by MCS. Based on MCS, the effect of the thyroid
collar to the backscatter was estimated to be < 3% and
therefore, no separated backscatter correction for the collar
was applied for patient measurements. It is assumed that
the air kerma (in the investigated energy range, this corre-
sponds to the absorbed dose in air and is in the following
taken as measure for the entrance surface dose) at the sur-
face in front of the thyroid was representative for the effect
on the thyroid dose.
Monte Carlo simulation
We used the Geant4 simulation toolkit [16]. A numerical
voxel phantom was created with the XCAT program [17]
(voxel size 2 × 2 × 2 mm3). Each voxel was assigned to an
organ. Considering the thyroid gland is as an extended
organ with an inhomogeneous dose distribution, the dose
was calculated based on the real anatomic situation
implemented in the voxel phantom. Accumulated dose was
calculated by absorbed energy divided by the voxel mass.
The x-ray beam was modelled by electrons with kinetic en-
ergies of 28 or 35 keV hitting a W-target inclined at 20°.
The radiation was filtered with 50-μm Rh according to the
Siemens Mammomat Inspiration manual specifications.
The beam opening angle was chosen to fully cover the
compression plate. In the model, the x-ray head was simpli-
fied as a lead cube of 1-mm wall thickness (shielding of 1E-
9 at 35 keV) with a rectangular hole in the bottom. Dis-
tances and dimensions were modelled according to the Sie-
mens Mammomat Inspiration manual specifications and
on-site measurements. The breast tissue was assumed to be
a mixture of fat and glandular tissue (ratio 3:2). According
to Verdù et al. [18], different breast tissue compositions
have been investigated and the uncertainty of tissue com-
position onto the glandular dose was estimated to be ± 10%
for adipose tissue ratios of 40%, 50% and 60%. From the
simulated thyroid dose of approximately 100 pGy, we ex-
pected a fluence of 59 cm−2 through the thyroid. Assuming
an area of 4 cm2 for the thyroid, we expected 200 photons
with an additional uncertainty of 7%. A standard low-
energy package was used as recommended in literature
[19]. The MCS toolkit was used to calculate all organ doses
defined by the ICRP 103 recommendations [20]. The effect-
ive dose was calculated on the basis of these organ doses by
applying the ICRP 103 model.
Results
Compared to the patient study, we found a more pro-
nounced increase for the scatter dose with increasing
thickness of PMMA slabs (for 7 cm compared to 3 cm
factor 4.2 in Fig. 3, blue line). For the air kerma in the pa-
tient measurement, we found an average increase clearly
below a factor of 4 (Fig. 4; factor 2.4 with exponential fit).
Fig. 2 Patient measurement (MLO view) with modified thyroid
protection collar and external dosimeter.
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The measurements dedicated to evaluate spatial/an-
gular scatter contributions without Alderson phantom
(sensors attached on a thin PMMA plate at thyroid
positions) and with a SEQ-6R dosimeter (which has a
more isotropic response) revealed higher dose values
(red squares in Fig. 3), indicating dose contributions
coming from different angles. The green triangle in
Fig. 3 represents a measurement with SEQ-6R
dosimeter with a Pb-shield directed upward for omit-
ting the scattered radiation and leakage radiation
coming from the collimator system. Additional mea-
surements using this Pb-shielding downward (directed
to the scatter coming from the PMMA slabs) indi-
cated that both directions contribute more or less
equally with a dose of 58 μGy for one CC exposure
with 30 kV and 100 mAs. Comparing the exponential
fits in Fig. 3 (values for one CC view, measured with
RQM-sensor) and Fig. 4 (one CC view and one MLO
view, measured with SEQ dosimeter), the air kerma
values were clearly higher for the patients. At 6 cm,
one CC view results in a dose of 30 μGy (Fig. 3). In
Fig. 4, the corresponding value for a single view can
be estimated by the half of the value and was 100
μGy. The discrepancy was smaller for the measure-
ment with the SEQ dosimeter in Fig. 3 (for the
directed measurement / green triangle, 58 mGy which
is slightly more than the half of the patient value).
In Table 1, the exposure parameters for phantom and
patient measurements are summarised, where tube volt-
age and current were a result of the automatic dose con-
trol (OPDOSE). The average compression thickness was
55.5 mm for the CC view and 57.1 mm for the MLO view.
The scatter plot showing the relation between the air
kerma and body mass index (BMI) is presented in Fig. 5.
It reveals a weak correlation (Pearson r = 0.48).
In Table 2, the mean air kerma values (scattered
dose values for patients) in front of and behind the
collar are displayed. The difference in measured dose
was significant (p < 0.001), but behind the collar, a
higher dose value than that expected from the lead
equivalent value was observed (6–10% of the dose
values in front of the collar, at 35 kV; < 0.1% was ex-
pected for 0.25 mm Pb and direct beam transmis-
sion). No significant difference in the dose values
measured behind the collar among L-group, M-group
and S-group was found (p ≥ 0.332).
The dose values presented in Table 2 cannot be com-
pared directly to the thyroid doses, since the values in
this Table are air kerma values. For organ doses, the
absorption of the tissue under consideration of the inci-
dent beam angle has to be applied and the dose values
have to be converted from air to tissue. The MCS calcu-
lation with a beam quality for a tube voltage in the range
of 28–35 kV and an average breast entrance dose
Fig. 3 Compression thickness dependence of surface dose (Kair = air kerma) at the position of the thyroid gland (phantom measurements) for one CC
view. Blue dots represent measures obtained with a PMMA phantom mimicking the compressed breast tissue and the patient’s body represented by
an Alderson phantom; the measurements were taken with a RQM sensor directed horizontally to the beam, perpendicular to the beam axis (see Fig.
1). Red squares indicate measurements with the same PMMA slab phantom, but without Alderson phantom. The measurements were performed with
a SEQ-6R dosimeter. Green triangle represents a measurement with SEQ-6R dosimeter using a Pb-shield directed upward to omit scatter and leakage
radiation coming from the collimator system. Error bars represent standard deviations. The blue solid line is an exponential fit to the blue
dots: Kair = 3.837μGy ⋅ exp(0.3433cm−1 ⋅ Compression).
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(automatic calculation for each exposition by the Mam-
momat software and available in DICOM data for each
examination) of 3.6 mGy observed in the patient study
(3.4 ± 1.4 mGy for the CC view and 3.7 ± 1.8 mGy for
the MLO view) resulted in a thyroid dose from 4.3 μGy
(28 kV) to 5.8 μGy (35 kV) for a two-view bilateral
mammography. The corresponding air kerma values on
the surface at thyroid position calculated by the MCS
were 158 μGy (28 kV) and 162 μGy (35 kV) for a two-
view bilateral mammography with the same average en-
trance or MGD as found in the patient study. This was
approximately the half of the average air kerma outside
value in the patient measurement shown in Table 2 (187
μGy for left breast, 374 μGy for a full four-view
mammography). The air kerma value measured with
PMMA breast phantom was approximately 80 μGy for
one CC exposition and 5.55 cm compression (estimated
by interpolating the data / red squares shown in Fig. 3).
Thus, a two-view bilateral mammography therefore
sums up to approximately 320 μGy, a value close to the
surface dose found in the patient study. Table 3 presents
an overview of surface dose values originating from dif-
ferent studies.
For a two-view bilateral mammography, the MCS
resulted in an effective dose of 214 μSv (28 kV) and
234 μSv (35 kV) for the average entrance dose found
in the patient study. The contribution of MGD to the
effective dose is 98.6% (28 kV) and 98.0% (35 kV).
Fig. 4 Compression thickness dependence (CC direction) of surface dose (Kair = air kerma = outside dose) at the position of the thyroid gland in
patients. The values for air kerma are given for one CC view and one ML view. Tube voltage and tube current × time have been regulated by the
automatic exposure control in the range of 26–32 kV and 36–237 mAs, respectively. The blue solid line is an exponential fit to the blue
dots: Kair = 52.87μGy ⋅ exp(0.2194cm−1 ⋅ Compression).
Table 1 Tube voltage (kV) and tube current – time products (mAs) for phantom and patient measurements
Group / Type Tube voltage (kV; single value,
range, or mean ± standard
deviation)
Tube current (mAs; single value,
range, or mean ± standard
deviation)
Compression thickness
(mm; single value, range,
or mean ± standard deviation)
CC MLO CC MLO CC MLO
Breast phantom without
Alderson, two different
compression thicknesses
28 80 50
30 100 60
Breast phantom with Alderson 26–30 27–30 52–231 51–240 30–70 30–70
Patient L-group 30.2 ± 0.8 30.6 ± 0.9 105.4 ± 26.5 119.6 ± 36.4 67.3 ± 7.8 70.2 ± 9.0
Patient M-group 29.5 ± 0.8 29.7 ± 0.9 101.8 ± 30.9 111.1 ± 41.1 59.4 ± 7.7 60.6 ± 9.5
Patient S-group 28.0 ± 0.9 28.2 ± 0.9 79.3 ± 28.3 82.7 ± 20.1 43.9 ± 9.3 44.9 ± 7.4
All patients 29.1 ± 1.3 29.4 ± 1.4 93.6 ± 30.6 102.0 ± 35.9 55.5 ± 17.7 57.1 ± 13.9
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The relative dose contributions to the different organs
are given in Table 4. The highest exposition (of a pa-
tient of the L-group) would lead to a maximum ef-
fective dose of 300 μSv.
The application of the thyroid collar was quick and
that did not slow down the workflow. It took about 3–5 s
and was easily done by an experienced radiology techni-
cian. The patients in our study did not complain of com-
pression or pain, but most of them thought that to have a
thyroid collar around the neck in an already emotional
situation was rather uncomfortable.
The image quality of mammograms was found to
be state-of-the-art without differences regarding the
right mammograms without thyroid collar and the left
mammograms with thyroid collar. In none of the
cases the collar was visible on the images. In three
cases, one retake was necessary because the dosimeter
was visible in the image (these measures were not in-
cluded in the dose calculation).
Discussion
The thyroid protection used in this study significantly
reduced the air kerma, which was assumed to be propor-
tional to the scattering dose to the thyroid. Due to scat-
ter, the air kerma behind the protective collar was higher
than expected from the lead equivalent value (16 ± 2
μGy in average for all patients; see Table 2). According
the thickness of the lead of 0.25 mm, the incident beam
was expected to be attenuated by a factor of 15.10–5.
The dose we estimated behind the collar is in agreement
with the findings reported by Ramalho et al. (18 μGy)
[11]. Measurements with phantoms revealed scatter
contributions (50%) from upside (collimator system) and
downside (backscatter form breast and detector system,
50% of the total contribution; see Fig. 3, green triangle),
resulting in air kerma values up to > 100 μGy for 6-cm
compression at the surface of thyroid position. This
value is clearly greater than the values found in the MCS
but corresponds to the values we found in the patient
Fig. 5 Scatter plot of air kerma (Kair) in front of the thyroid protection device with body mass index and so, approximately, with breast volume.
The BMI correlates less (R = 0.48) to backscatter than compression thickness because even large breasts may sometimes have only a thin
compression thickness. Therefore, the determining factor for backscatter is compression thickness: Kair = − 60.75μGy + 10.29μGy ⋅ BMI.
Table 2 Left: mean dose (air kerma ± standard error) in front of (outside dose) and behind thyroid protection (inside dose), groups
L = large, M =medium, S = small; measured values for 1× CC and 1× MLO left breast. Right: Results of ANOVA and Tukey’s range test.
Measured values for one craniocaudal view and one mediolateral oblique view of the left breast. Left: paired t-test. Right: ANOVA
and Tukey’s range test
Group Outside dose (mGy) Inside dose (mGy) p value Comparison Outside dose p value Inside dose p value
All (n = 82) 0.187 ± 0.011 0.016 ± 0.002 < 0.001 Overall < 0.001 0.364
L-group (n = 27) 0.249 ± 0.016 0.020 ± 0.004 < 0.001 L-group vs M-group 0.019 0.813
M-group (n = 22) 0.182 ± 0.019 0.017 ± 0.004 < 0.001 L-group vs S-group < 0.001 0.332
S-group (n = 33) 0.141 ± 0.014 0.013 ± 0.003 < 0.001 M-group vs S-group 0.190 0.762
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study. In the MCS, 85% of the dose came from backscat-
ter of breast and detector system and only 15% was
caused by collimator scatter.
In comparison to the patient study, only the half value
of the air kerma at the surface was found by the MCS. As
indicated by the red squares and green triangle in Fig. 3,
approximately half of the measured air kerma was con-
tributed by scatter or leakage radiation coming from the
tube/collimator system. To cover the collimator scatter
more appropriately, the collimator system should be im-
plemented in more detail in the MCS model. In front of
the thyroid, for a two-view bilateral mammography, the
experiment measured an air kerma of 374 μGy while the
MCS measured only 162 μGy. The experimental value
was higher than the MCS by a factor of 2.3. We estimate
the influence on the effective dose by increasing all 15
organ doses according to ICRP 103 [20] except on the dir-
ectly irradiated breast by this factor 2.3. The effective dose
increases by < 4%. This is due to the large fraction of total
effective dose in the irradiated breast (~ 97%).
The thyroid dose calculated by MCS with the parame-
ters according to the average patient in the patient study
was in the range of 4–6 μGy (depending on the tube
voltage) for a two-view bilateral mammography and 1–1.
Table 3 Summary of surface and thyroid dose values found in the different studies
Monte Carlo
simulation
Phantom
measurement
Patient study
Surface dose at thyroid position, 4 views, current study, Siemens
Mammomat
158 μGy (28 kV)
162 μGy (35 kV)
~ 320 μGy
(compression
5.55 cm)
374 μGy
(29 kVp, 98 mAs per view
average, 0.95 μGy/mAs)
Surface dose at thyroid position 4 views, Chetlen et al. [8], Senograph
Essential, GE Health Care
240 μGy (right lobe)
250 μGy (left lobe)
(29 kVp, 58 mAs per view in
average, 1.06 at 29 kVp)
Surface dose at thyroid position 4 views, Whelan et al. [7], Senograph
DMR, GE Health Care
390 μGy
(average 1.05 μGy /mAs)
Surface dose (4 films), Kunosic et al. [9] 220 μGy
Surface dose at thyroid position, 4 views. Estimated by the ratio of our
MCS and Sechopoulos et al. [1]
38–126 μGy
Thyroid dose resulting from bilateral digital mammography examination
in CC view; Baptista et al. [10]
273 μGy
Surface dose at thyroid position, Ramalho et al. [11], GE Senograph 160 μGy
(compression
4.5 cm)
Table 4 Relative dose contributions to the effective dose, calculated by Monte Carlo simulation
Organ group /
Tissue
Relative contribution to effective dose (no leakage radiation from x-ray head)
35 kV 28 kV
Red bone marrow 0.40% 0.30%
Stomach wall 0.04% 0.02%
Bladder 0.00% 0.00%
Liver 0.01% 0.00%
Cortical bone 0.03% 0.02%
Oesophagus 0.01% 0.00%
Salivary gland 0.09% 0.09%
Skin 0.54% 0.50%
Brain 0.00% 0.00%
Lung 0.69% 0.36%
Breast 97.99% 98.55%
Thyroid 0.10% 0.08%
Gonades (female) 0.00% 0.00%
Intestine 0.01% 0.01%
ICRP103_Rest 0.08% 0.06%
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5 μGy for one CC exposition. Sechopoulos et al. re-
ported a thyroid dose for each mammographic view of 0.
016–0.045% of the MGD, depending on the view needed
and exposure parameters/beam quality [1, 3]. In our pa-
tient study, with an average MGD of 0.9 mGy for one
CC view, this would result in a thyroid dose of 0.144–0.
405 μGy. Of note, the MGD found by our patient study
is in accordance with data reported by Bosmans et al.
[21]. For a two-view bilateral mammography, this sums
up to a thyroid dose in the range of 0.7–1.6 μGy. Based
on this value and the ratio between thyroid dose and air
kerma found by the MCS model, we can expect an air
kerma of 38–126 μGy. In Table 3, this range is compared
to surface dose values found by other studies. Whelan et
al. reported a surface dose (skin overlying the thyroid) of
0.39 ± 0.22 mGy [7]. This surface dose value is similar to
the results of our patient study and is higher than the
value found by Chetlen et al. (0.250 ± 0.116 mGy) or by
Kunosic et al. (0.220 ± 0.01 mGy). In our patient study,
the average tube voltages are comparable to those re-
ported in the patient study by Chetlen et al. [8]. The
average compression thickness was slightly below the
values found by Chetlen et al. [8] (58–59 mm for the CC
view and 62–63 mm for the MLO view). The trend of
the BMI in Fig. 5. is in line with Chetlen et al. [8] and
can be attributed to the fact that large breasts can some-
times still be compressed to low thicknesses. Our results
for the surface dose in the patient study (374 ± 11 μGy
in average) correspond to a thyroid dose of approxi-
mately 10 ± 2 μGy when applying a conversion factor de-
rived by the comparison of the surface dose values of
MCS (4.3 μGy) and measurement, both at 28 kV (air
kerma[patient] / air kerma[MCS] = 374 mGy / 158 mGy
= 2.367). This is in agreement with the phantom study
reported by Ali et al. (9.5 μGy measured by thermo-
luminescence dosimeter in an ATOM phantom) [22].
Baptista et al. [10], using MCS, found a thyroid dose of
0.273 mGy for the CC view with a corresponding breast
MGD of 2 mGy. Compared to our MCS and those re-
ported in the literature, this result is surprisingly high
for the organ dose value.
In contrast to the change in MGD found in patients by
Bosmans et al. [21], we found a more pronounced increase
for the scatter dose with increasing thickness of PMMA-
slabs (for a 7-cm compared to a 3-cm compression thick-
ness). In our phantom measurements, the higher density
of the PMMA plate and, related to this, the higher mAs
and kV values selected by the automatic dose control led
to a more pronounced rise of the dose with increasing
compression thickness. We should note that the PMMA
slabs do not perfectly simulate the breast glandular tissue.
Therefore, patient measurements are important. The pa-
tient measurements do support the phantom study and
take into account the real anatomic variability in women
(morphology and mobility of the neck, difference in breast
density, and difference in thyroid–breast distance). How-
ever, the variability found in our study is smaller than that
reported by Whelan et al. [7].
The effective dose we calculated by MCS for the pa-
rameters according to the average patient in the patient
study was approximately 0.2–0.3 mSv, lower than the ef-
fective dose reported by Ali et al. (0.326 mSv) [22],
reflecting the tendency for differences between MCS and
measurements. The contribution of the thyroid was
small compared to the breast dose. From this point of
view, the relevance of the use of a protective collar may
be questionable in a routine clinical setting.
It is important to have data about real patient settings to
advise and reassure patients in case of questions about the
necessity and usefulness of a thyroid collar. The use of a
thyroid protection that does not obscure part of mammo-
gram (as we proposed) leads to a similar reduction in the
thyroid dose compared to a standard thyroid protection
device. However, with the sensitivity of the thyroid gland
for ionising radiation being more relevant in childhood
and young adulthood [2, 3], the proposed thyroid protec-
tion may be taken into consideration especially for young
women, outside the regular screening setting.
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